timothy sykes logo

Stock News

Nuvation Bio (NUVB) Surges Amid Major Regulatory Milestone in Japan

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 9/28/2025, 12:16 pm ET 9/28/2025, 12:16 pm ET | 5 min 5 min read
Nuvation Bio (NUVB) Surges Amid Major Regulatory Milestone in Japan Thumbnail

AstraZeneca announces collaboration milestone with Nuvation Bio Inc., stocks have been trading up by 7.64 percent.

Healthcare industry expert:

Analyst sentiment – positive

Nuvation Bio (NUVB) currently faces significant financial challenges but maintains strong cash liquidity. With a negative EBIT margin of -1408.7% and an enterprise value of $250.34 million, the company struggles with profitability. Despite these setbacks, NUVB holds a commendable current ratio of 9.4, reflecting solid short-term financial health. Key financial insights include a stark free cash flow deficit and substantial operating losses, underscoring critical issues in operational scalability. Their revenue of $7.87 million is overshadowed by extensive expenses, necessitating strategic interventions.

Analyzing NUVB’s technical indicators reveals bearish movements, as confirmed by recent weekly patterns. The stock’s close at $3.03 highlights resistance around $3.25, with near-term support at $3. Considering the lower highs and trending downward trajectory, a tactical recommendation is to implement a short position at current levels, targeting a break below $3. Volume trends suggest decreasing momentum, emphasizing continuation of the bearish trend unless significant reversal indicators materialize.

Recent regulatory successes in Japan for IBTROZI, alongside robust Phase 2 study outcomes, positions NUVB positively in the oncology landscape. The approval by Japan MHLW is a strategic victory that improves outlook and can catalyze future growth, enhancing investor sentiment. Comparison to benchmarks shows NUVB’s strategic progress in cancer treatment is commendable, yet it must effectively address financial sustainability. Given these dynamics, NUVB’s stock could potentially rise above resistance with sustained growth catalysts. Hence, outlook leans towards a positive long-term trajectory.

  • Parallel approval of a companion diagnostic further solidifies Nuvation Bio’s strategic position in the international pharmaceutical landscape.

  • High progression-free survival rates presented in Phase 2 TRUST-I and TRUST-II studies highlight substantial efficacy in treating advanced ROS1-positive NSCLC, bolstering Nuvation Bio’s clinical credentials.

  • A $25 million milestone payment is set to follow Japan’s reimbursement price setting for IBTROZI, anticipated in the fourth quarter, showcasing substantial commercial potential.

Candlestick Chart

Weekly Update Sep 22 – Sep 26, 2025: On Sunday, September 28, 2025 Nuvation Bio Inc. stock [NYSE: NUVB] is trending up by 7.64%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In recent trading sessions, Nuvation Bio’s stock oscillated with notable fluctuations, highlighting investor reactions to groundbreaking regulatory news. The stock opened at $3.27 but saw a downward dip reaching a closing value of $3.20. Reflective of market volatility, the price saw some recovery, closing at $3.24 on September 26. These movements indicate a market grappling with both optimism from regulatory wins and cautious deliberation over commercial impacts.

Financially, Nuvation Bio’s profitability ratios reveal an operational landscape marked by significant margins except for gross margin, which is positive at 27.5%. Severe negative metrics such as EBIT and EBITDA margins illustrate operational challenges. Despite high enterprise value and price-to-sales ratio of 76.3, the stock struggles with profitability, indicating structural inefficiencies yet to be resolved. The company’s cash position remains robust with $247.97 million, laying a financial foundation for potential strategic expansions post-regulatory wins.

The news of Japan’s regulatory approval and anticipated $25 million milestone payment imbues Nuvation Bio with strategic momentum; however, the company’s financial statements necessitate a cautious interpretation of long-term market potential. While investors may hope to capitalize on current hype, careful attention to operational fundamentals is crucial.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”